Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
Status:
Completed
Trial end date:
2018-07-24
Target enrollment:
Participant gender:
Summary
To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in
subjects with mild or moderate Hepatic impairment compared to subjects with normal hepatic
function